Tumor apoptosis induced by ruthenium(II)‐ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor

Ketoconazole (KTZ) has been used as a second‐line agent in hormone‐refractory cancer therapy. Since transition metal complexes including those of Ru(III), show important anticancer activity with limited toxicity, we investigated the potential antitumor efficacy of Ru(II) complexed to KTZ or clotrima...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2004-11, Vol.112 (3), p.376-384
Hauptverfasser:	Strasberg Rieber, Mary, Anzellotti, Atilio, Sánchez‐Delgado, Roberto A., Rieber, Manuel
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - pharmacology Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - pharmacology Apoptosis - drug effects bcl-2 Homologous Antagonist-Killer Protein Biological and medical sciences C225 MAb Caspase 3 Caspases - metabolism caspase‐3 cleavage Cisplatin - administration & dosage Clotrimazole - administration & dosage Combined Modality Therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Cytochromes c - metabolism Drug Synergism Enzyme Activation - drug effects epidermal growth factor Humans Ketoconazole - administration & dosage Medical sciences Membrane Proteins - metabolism Mitochondria - drug effects Neoplasms - metabolism Neoplasms - pathology PARP fragmentation Pharmacology. Drug treatments Poly(ADP-ribose) Polymerases Receptor, Epidermal Growth Factor - immunology Ru(II) Ruthenium Compounds - administration & dosage Ruthenium Compounds - therapeutic use Spheroids, Cellular - pathology Superoxide Dismutase - metabolism Tumor Cells, Cultured Tumor Suppressor Protein p53 - metabolism Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!